Compare Alexandria Real Estate Equities Inc (ARE) vs Moderna, Inc. (MRNA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alexandria Real Estate Equities Inc vs Moderna, Inc. — how do they compare? Alexandria Real Estate Equities Inc trades at $47.87 (market cap $8.34B), while Moderna, Inc. trades at $67.98 (market cap $27.09B). The key difference: Moderna, Inc. is far larger — about 3.2× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays a 6.02% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| ARE | MRNA | |
|---|---|---|
Market Cap | $8.34B | $27.09B |
Sector | Real Estate | Health |
52-Week High | $87.45 | $81.80 |
52-Week Low | $40.41 | $22.36 |
Enterprise Value | $20.80B | $23.18B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Alexandria Real Estate Equities (ARE) trades at $47.88, down 1.3% on the day, with a bearish technical signal and mixed fundamentals. The stock shows a high P/E of 102.99 and negative net income margin of -37.09%, though it maintains a strong gross margin of 67.76% and positive operating cash flow. Recent news highlights corporate responsibility initiatives and a declared dividend of $0.72 per share for Q2 2026.
The outlook is cautious due to profitability challenges and elevated debt, but analyst consensus suggests moderate upside to a $51.00 price target. Key risks include sustained negative earnings and interest rate sensitivity, while institutional sentiment leans neutral with 58.33% hold ratings.
Moderna (MRNA) trades at $68.27, down 10.83% amid a biotech sell-off, but maintains a bullish technical trend with strong moving averages. Revenue has declined from pandemic peaks to $1.92B in 2025, with net losses widening to -$2.82B, yet recent quarterly EPS beats and pipeline expansions into oncology and flu vaccines fuel optimism. The stock remains volatile, with a consensus price target of $49.00 below the current price, reflecting mixed analyst sentiment.
The outlook hinges on pipeline execution, with EU RSV vaccine contracts and FDA decisions offering upside, but high cash burn and competitive pressures pose risks. Investors face a trade-off between growth potential and profitability challenges, with the stock's 70% monthly surge testing sustainability near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alexandria Real Estate Equities Inc
Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.
Read more on ARE →About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →
